VYDURA

This brand name is authorized in Austria, Croatia, Estonia, France, Italy, Lithuania, Romania, Spain.

Active ingredients

The drug VYDURA contains one active pharmaceutical ingredient (API):

1	Rimegepant UNII 1383NM3Q0H - RIMEGEPANT SULFATE
	Rimegepant selectively binds with high affinity to the human calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function. The relationship between pharmacodynamic activity and the mechanism(s) by which rimegepant exerts its clinical effects is unknown.
	Read more about Rimegepant

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VYDURA Oral lyophilisate	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N02CD06		N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CD Calcitonin gene-related peptide (CGRP) antagonists
Discover more medicines within N02CD06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1882144, 1882155
ES	Centro de información online de medicamentos de la AEMPS	1221645002
FR	Base de données publique des médicaments	65899221
IT	Agenzia del Farmaco	050080011, 050080023, 050080035
LT	Valstybinė vaistų kontrolės tarnyba	1094639, 1094640
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68828001, W68828002